Much bias, little binary: in sex differences in gene expression, "the whole genome is in the game" July 30, 2019
Mallinckrodt deal signals turnaround for Silence at potential $693M per target July 22, 2019 By Nuala Moran LONDON – Silence Therapeutics plc has finally secured a deal to transform its fortunes, signing up Mallinckrodt plc in a potential $693 million-per-asset collaboration to develop siRNA therapeutics that block the complement inflammatory cascade.Read More
RSS